Were doing it because different brand names of the same generic medication have been approved for different indications, so we dont want to cause confusion
The introduction of sodium-glucose cotransporter-2 inhibitors (SGLT2is), glucagon-like peptide receptor agonists (GLP-1RAs), and nonsteroidal mineralocorticoid receptor antagonists (nsMRAs) has reshaped clinical guidelines in recent decades
Given these roles, GSH has emerged as a promising therapy and biomarker in neurodegenerative diseases
Who May Be at Higher Risk for Mental Health Side Effects
Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans
18-h: j , k ) (n = 3, two-sided unpaired t-test)